Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a diagnosis of type 2 diabetes mellitus~* Hemoglobin A1c levels \>=7% and \<=10.5%~* taking a stable daily dose of metformin~* Body mass index (BMI) 25 to 45 kg/m2 except those of Asian descent who must have a BMI of 24 to 45 kg/m2~* Stable body weight~* Serum creatinine \<=1.5 mg/dL (132.6 umol/L) for men and \<=1.4 mg/dL (123.76 umol/L) for women~Exclusion Criteria:~* Patients must not have prior exposure or known contraindication or suspected hypersensitivity to canagliflozin (JNJ-28431754)~* Known contraindication or suspected hypersensitivity to sitagliptin or metformin~* A history of diabetic ketoacidosis or type 1 diabetes mellitus~* History of pancreas or beta-cell transplantation~* History of active proliferative diabetic retinopathy~* History of hereditary glucose-galactose malabsorption or primary renal glucosuria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Canagliflozin 50 mg daily (Type: EXPERIMENTAL): Each patient will receive 50 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
- Canagliflozin 100 mg daily (Type: EXPERIMENTAL): Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
- Canagliflozin 200 mg daily (Type: EXPERIMENTAL): Each patient will receive 200 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
- Canagliflozin 300 mg daily (Type: EXPERIMENTAL): Each patient will receive 300 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo capsule once daily (in the evening).
- Canagliflozin 300 mg twice daily (Type: EXPERIMENTAL): Each patient will receive 300 mg of canagliflozin (JNJ-28431754) twice daily for 12 weeks.
- Sitagliptin 100 mg daily (Type: ACTIVE_COMPARATOR): Each patient will receive 100 mg of sitagliptin once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
- Placebo (Type: PLACEBO_COMPARATOR): Each patient will receive matching placebo twice daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).